Cangrelor
Composition
Contains Cangrelor, an intravenous P2Y12 platelet inhibitor, supplied as a solution for injection.
Indications
Used to reduce thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) who are not pre-treated with oral P2Y12 inhibitors.
Side effects
Bleeding, dyspnea, hypotension, nausea.
Precautions
Monitor for bleeding; use cautiously in patients with bleeding risk or recent stroke.
Contraindications
Active pathological bleeding, history of intracranial hemorrhage, hypersensitivity to Cangrelor.
Dosage and administration
Continuous IV infusion of 30 mcg/kg/min during PCI; start oral P2Y12 inhibitor immediately after stopping infusion.
Countries
Available Forms
Injectable solution for IV infusion.